DYRK1A increased in the brains of patients with AD (Kimura et al., 2007) and DS (Ryoo et al., 2008) DYRK1A expression in DS brain correlates with 3-repeat tau levels (Shi et al., 2008; Wegiel et al., 2011) Plasma DYRK1A positively correlates with cerebrospinal fluid tau and phospho-tau in AD patients (Janel et al., 2014) Co-localization of DYRK1A with NFTs greater in AD-DS than SAD (Wegiel et al., 2008) REST levels correlate with cognitive preservation and longevity in aging and are downregulated in AD (Lu et al., 2014). Here, MAPT is linked to Alzheimer disease.